Invesco Health Care Fund

Equity | Sector Equity

Objective & Strategy

The fund seeks long-term growth of capital by investing in equity securities of health care companies throughout the world.

as of 11/30/2019

Morningstar Rating

Overall Rating - Health Category

As of 11/30/2019 the Fund had an overall rating of 3 stars out of 135 funds and was rated 3 stars out of 135 funds, 3 stars out of 121 funds and 2 stars out of 102 funds for the 3-, 5- and 10- year periods, respectively.

Morningstar details

Source: Morningstar Inc. Ratings are based on a risk-adjusted return measure that accounts for variation in a fund's monthly performance, placing more emphasis on downward variations and rewarding consistent performance. Open-end mutual funds and exchange-traded funds are considered a single population for comparison purposes. Ratings are calculated for funds with at least a three year history. The overall rating is derived from a weighted average of three-, five- and 10-year rating metrics, as applicable, excluding sales charges and including fees and expenses. ©2019 Morningstar Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not guarantee future results. The top 10% of funds in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. Ratings are subject to change monthly. Had fees not been waived and/or expenses reimbursed currently or in the past, the Morningstar rating would have been lower. Ratings for other share classes may differ due to different performance characteristics.

Management team

as of 10/31/2019

Top Equity Holdings | View all

  % of Total Assets
Thermo Fisher Scientific 4.52
Medtronic 4.45
Novartis ADR 4.42
UnitedHealth 4.38
AstraZeneca 4.09
Johnson & Johnson 4.08
Merck 3.39
Sanofi ADR 2.67
Abbott Laboratories 2.60
Zimmer 2.50

May not equal 100% due to rounding.

Holdings are subject to change and are not buy/sell recommendations.

as of 11/30/2019 09/30/2019

Average Annual Returns (%)

  Incept.
Date
Max
Load (%)
Since
Incept. (%)
YTD (%) 1Y (%) 3Y (%) 5Y (%) 10Y (%)
NAV 08/07/1989 N/A 10.77 24.83 12.99 12.80 5.56 11.91
Load 08/07/1989 5.50 10.56 17.96 6.76 10.69 4.37 11.28
NAV 08/07/1989 N/A 10.38 10.35 -3.95 6.40 4.10 10.84
Load 08/07/1989 5.50 10.17 4.27 -9.23 4.41 2.93 10.21
Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Investment return and principal value will vary so that you may have a gain or a loss when you sell shares.

Performance shown at NAV does not include applicable front-end or CDSC sales charges, which would have reduced the performance.

Performance figures reflect reinvested distributions and changes in net asset value (NAV) and the effect of the maximum sales charge unless otherwise stated.

as of 11/30/2019 09/30/2019

Annualized Benchmark Returns


Index Name 1 Mo (%) 3 Mo (%) 1Y (%) 3Y (%) 5Y (%) 10Y (%)
MSCI Wld Hlth Cr ND IX 4.73 9.84 9.57 14.13 7.22 12.15
MSCI World IX ND 2.79 7.64 14.53 12.35 7.75 9.34
MSCI Wld Hlth Cr ND IX -0.10 -1.25 -1.83 8.01 6.38 11.65
MSCI World IX ND 2.13 0.53 1.83 10.21 7.18 9.01

Source: RIMES Technologies Corp.

Source: RIMES Technologies Corp.

An investment cannot be made directly in an index.

Expense Ratio per Prospectus

Management Fee 0.63
12b-1 Fee 0.25
Other Expenses 0.21
Interest/Dividend Exp 0.00
Total Other Expenses 0.21
Acquired Fund Fees and Expenses (Underlying Fund Fees & Expenses) 0.01
Total Annual Fund Operating Expenses 1.10
Contractual Waivers/Reimbursements N/A
Net Expenses - PER PROSPECTUS 1.10
Additional Waivers/Reimbursements 0.00
Net Expenses - With Additional Fee Reduction 1.10
This information is updated per the most recent prospectus.

Historical Prices

From   to
No history records found for this date range
Date Net Asset Value ($) Public Offering Price ($)
{{histTableData.rateDate | date : 'MM/dd/yyyy'}} {{histTableData.netAssetValue | numberValue}} {{histTableData.offeringPrice | numberValue}}

Distributions

From   to
    Capital Gains Reinvestment
Price ($)
Ex-Date Income Short Term Long Term
{{distribution.rateDate | date : 'MM/dd/yyyy'}} {{distribution.dividendFactor | numberValue:4:'N/A'}} {{distribution.capGainsFactorShort | numberValue:4:'N/A'}} {{distribution.capGainsFactorLong | numberValue:4:'N/A'}} {{distribution.reinvestmentPrice | numberValue:3:'N/A'}}
as of 10/31/2019

Sector Breakdown

Holdings % of Total Net Assets
CASH/OTHER 1.40
Consumer Staples 0.70
Health Care 97.90

May not equal 100% due to rounding.

The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.

as of 11/30/2019

Fund Characteristics

3-Year Alpha N/A
3-Year Beta N/A
3-Year R-Squared N/A
Number of Securities N/A
Total Assets $1,439,320,764.00
Wghtd Med Mkt Cap MM$ $73,194.00

Source: RIMES Technologies Corp.,StyleADVISOR

Benchmark:  N/A

as of 10/31/2019

Top Equity Holdings | View all

  % of Total Assets
Thermo Fisher Scientific 4.52
Medtronic 4.45
Novartis ADR 4.42
UnitedHealth 4.38
AstraZeneca 4.09
Johnson & Johnson 4.08
Merck 3.39
Sanofi ADR 2.67
Abbott Laboratories 2.60
Zimmer 2.50

May not equal 100% due to rounding.

Holdings are subject to change and are not buy/sell recommendations.

as of 10/31/2019

Top Countries

  % of Total Assets
United States 74.53
Switzerland 6.94
United Kingdom 4.09
Brazil 2.86
France 2.79
Denmark 2.48
Netherlands 1.77
Japan 1.32
Luxembourg 0.97
Ireland 0.49

May not equal 100% due to rounding.

as of 10/31/2019

Top Industries

  % of Total Assets
Pharmaceuticals 33.82
Health Care Equipment 18.70
Biotechnology 16.45
Managed Health Care 12.72
Life Sciences Tools & Services 8.47
Health Care Services 2.81
Health Care Supplies 2.01
Health Care Facilities 1.62
Health Care Technology 1.29
Drug Retail 0.67

May not equal 100% due to rounding.

The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.